Till startsida
To content Read more about how we use cookies on gu.se

Review articles

Review articles 2000-2010 with links to abstrakt in pubmed.


Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.
Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K.Nat Rev Drug Discov. 2010 Jul;9(7):560-74. R

Biochemical markers in Alzheimer's disease clinical trials.
Zetterberg H, Mattsson N, Shaw LM, Blennow K. Biomark Med. 2010 Feb;4(1):91-8. Review.

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall.
Mattsson N, Blennow K, Zetterberg H. Clin Chem Lab Med. 2010 May;48(5):603-7. Review.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Blennow K, Hampel H, Weiner M, Zetterberg H. Nat Rev Neurol. 2010 Mar;6(3):131-44. Epub 2010 Feb 16. Review.

CSF biomarkers: pinpointing Alzheimer pathogenesis.
Mattsson N, Blennow K, Zetterberg H. Ann N Y Acad Sci. 2009 Oct;1180:28-35. Review 

Total and phosphorylated tau protein as biological markers of Alzheimer's disease. 
Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Exp Gerontol. 2010 Jan;45(1):30-40. Epub 2009 Oct 22. Review.                                                                     

Amyloid beta and APP as biomarkers for Alzheimer's disease.          Zetterberg H, Blennow K, Hanse E. Exp Gerontol. 2010 Jan;45(1):23-9. Epub 2009 Aug 19. Review

Cerebrospinal fluid biomarkers for Alzheimer's disease.                    Blennow K, Zetterberg H. J Alzheimers Dis. 2009 Oct;18(2):413-7. Review

Future screening for incipient Alzheimer's disease--the influence of prevalence on test performance.                                              Mattsson N, Zetterberg H. Eur Neurol. 2009;62(4):200-3. Epub 2009 Jul 15. Review

Biomarkers in cerebrospinal fluid and blood in memory complaints Zetterberg H, Andreasen N, Blennow K. Lakartidningen. 2009 May 13-19;106(20):1386-9. Review. Swedish. 

Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases.                                                 Westman-Brinkmalm A, Ruetschi U, Portelius E, Andreasson U, Brinkmalm G, Karlsson G, Hansson S, Zetterberg H, Blennow K.Front Biosci. 2009 Jan 1;14:1793-806. Review

Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease.                                                                                   Zetterberg H. Scand J Clin Lab Invest. 2009;69(1):18-21. Review

Synaptic retrogenesis and amyloid-beta in Alzheimer's disease.      Wasling P, Daborg J, Riebe I, Andersson M, Portelius E, Blennow K, Hanse E, Zetterberg H. J Alzheimers Dis. 2009 Jan;16(1):1-14. Review

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. 
Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Alzheimers Dement. 2008 Jan;4(1):38-48. Epub 2007 Dec 21. Review                                                                               

Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders.                      Constantinescu R, Zetterberg H, Holmberg B, Rosengren L. Parkinsonism Relat Disord. 2009 Mar;15(3):205-12. Epub 2008 Jun 17. Review

Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?                                                                                        Zetterberg H.Recent Pat CNS Drug Discov. 2008 Jun;3(2):109-11. Review

Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K. Expert Rev Proteomics. 2008 Apr;5(2):225-37. Review

Amyloid-related biomarkers for Alzheimer's disease.                         Andreasen N, Zetterberg H.Curr Med Chem. 2008;15(8):766-71. Review

Clinical proteomics in neurodegenerative disorders.                          Zetterberg H, Rüetschi U, Portelius E, Brinkmalm G, Andreasson U, Blennow K, Brinkmalm A. Acta Neurol Scand. 2008 Jul;118(1):1-11. Epub 2008 Feb 13. Review

Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease.  
Höglund K, Blennow K.CNS Drugs. 2007;21(6):449-62. Review                                  

Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease.
de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H. Ann N Y Acad Sci. 2007 Feb;1097:114-45. Review

Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup.                                                 Wahlund LO, Almkvist O, Blennow K, Engedahl K, Johansson A, Waldemar G, Wolf H. Top Magn Reson Imaging. 2005 Dec;16(6):427-37. Review

Alzheimer's disease.                                                                       Blennow K, de Leon MJ, Zetterberg H. Lancet. 2006 Jul 29;368(9533):387-403. Review

Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease.                                                                                        Höglund K, Wallin A, Blennow K. Acta Neurol Scand Suppl. 2006;185:87-92. Review

The role of biomarkers in clinical trials for Alzheimer disease.      
Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E. Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):6-15. Review

There is a strong evidence that professional boxing results in chronic brain damage. The more head punches during a boxer's career, the bigger is the risk                                                                   
Blennow K, Popa C, Rasulzada A, Minthon L, Wallin A, Zetterberg H.Lakartidningen. 2005 Sep 5-11;102(36):2468-70, 2472-5. Review. Swedish.

The link between cholesterol and Alzheimer's disease.               
Sjögren M, Blennow K. World J Biol Psychiatry. 2005;6(2):85-97. Review

Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.                                           
Wiltfang J, Lewczuk P, Riederer P, Grünblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K. World J Biol Psychiatry. 2005;6(2):69-84. Review

CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment.   
Blennow K. Expert Rev Mol Diagn. 2005 Sep;5(5):661-72. Review                                           

CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.         
Andreasen N, Blennow K. Clin Neurol Neurosurg. 2005Apr;107(3):165-73. Review                                                                

Cerebrospinal fluid protein biomarkers for Alzheimer's disease.
Blennow K. NeuroRx. 2004 Apr;1(2):213-25. Review

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC. J Intern Med. 2004 Sep;256(3):240-6. Review

CSF biomarkers for mild cognitive impairment. 
Blennow K. J Intern Med. 2004 Sep;256(3):224-34. Review              

Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. 
Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Möller HJ. J Neural Transm. 2004 Mar;111(3):247-72. Epub 2003 Dec 3. Review.                                                               

Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications.
Zetterberg H. Reprod Biol Endocrinol. 2004 Feb 17;2:7. Review

CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.                                                                          
Andreasen N, Sjögren M, Blennow K. World J Biol Psychiatry. 2003 Oct;4(4):147-55. Review

Clinical mass spectrometry in neuroscience. Proteomics and peptidomics.                                                                   
Davidsson P, Brinkmalm A, Karlsson G, Persson R, Lindbjer M, Puchades M, Folkesson S, Paulson L, Dahl A, Rymo L, Silberring J, Ekman R, Blennow K. Cell Mol Biol (Noisy-le-grand). 2003 Jul;49(5):681-8. Review

CSF markers for incipient Alzheimer's disease.                    
Blennow K, Hampel H. Lancet Neurol. 2003 Oct;2(10):605-13. Review

Cerebral pattern of pro- and anti-inflammatory cytokines in dementias.                                                                     
Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K. Brain Res Bull. 2003 Aug 15;61(3):255-60. Review

CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.    
Blennow K, Vanmechelen E. Brain Res Bull. 2003 Aug 15;61(3):235-42. Review 

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.                                           
Sjögren M, Andreasen N, Blennow K. Clin Chim Acta. 2003 Jun;332(1-2):1-10. Review

Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.                                                 
Andreasen N, Blennow K. Peptides. 2002 Jul;23(7):1205-14. Review

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.  
Blennow K, Vanmechelen E, Hampel H. Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. Review                                 

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.
Vanmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winblad B, Davidsson P, Blennow K. Mech Ageing Dev. 2001 Nov;122(16):2005-11. Review

New discoveries on Alzheimer disease: new biochemical markers can hopefully improve diagnosis.
Blennow K, Minthon L, Wallin A. Lakartidningen. 2000 Jan 12;97(1-2):6-10. Review. Swedish. No abstract available



Page Manager: Staffan Persson|Last update: 10/14/2011

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?